Denmark’s Novo Nordisk, the world’s largest maker of insulin, said that it expects high single-digit sales growth and around 10% operating profit growth in 2015, as it reported a rise in third-quarter net profit.
from WSJ.com: US Business http://ift.tt/102ImQk
via IFTTT
from WSJ.com: US Business http://ift.tt/102ImQk
via IFTTT
No comments:
Post a Comment